NCT06777238View on ClinicalTrials.gov

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

August 7, 2026

Study Completion Date

March 10, 2027

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

GZR18

Administered SC

DRUG

Placebo

Administered SC

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY

NCT06777238 - A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | Biotech Hunter | Biotech Hunter